- Academic Editor
-
-
-
Background: Epilepsy is one of the most common neurologic diseases, and
around 30% of all epilepsies, particularly the temporal lobe epilepsy (TLE), are
highly refractory to current pharmacological treatments. Abnormal synchronic
neuronal activity, brain glucose metabolism alterations, neurodegeneration and
neuroinflammation are features of epilepsy. Further, neuroinflammation has been
shown to contribute to dysregulation of neuronal excitability and the progression
of epileptogenesis. Flufenamic acid (FLU), a non-steroidal anti-inflammatory
drug, is also characterized by its wide properties as a dose-dependent ion
channel modulator. In this context, in vitro studies have shown that it
abolishes seizure-like events in neocortical slices stimulated with a
gamma-aminobutyric acid A (GABA
